|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400086712 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-09 11:32:25 |
|
注册时间: Date of Registration: |
2024-07-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
探究抑郁干预对轻度认知障碍患者记忆功能影响及其神经机制 |
|
Public title: |
Exploring the effects of depression intervention on memory function and its neural mechanisms in patients with mild cognitive impairment |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
探究抑郁干预对轻度认知障碍患者记忆功能影响及其神经机制 |
|
Scientific title: |
Exploring the effects of depression intervention on memory function and its neural mechanisms in patients with mild cognitive impairment |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴希希 |
研究负责人: |
陆晓 |
|
Applicant: |
Wu Xixi |
Study leader: |
Lu Xiao |
|
申请注册联系人电话: Applicant telephone: |
+86 177 6812 0809 |
研究负责人电话: Study leader's telephone: |
+86 134 0413 9812 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1010464860@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1010464860@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路300号,南京医科大学第一附属医院康复医学中心 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路300号,南京医科大学第一附属医院康复医学中心 |
|
Applicant address: |
Rehabilitation Center of The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, China |
Study leader's address: |
Rehabilitation Center of The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Nanjing Medical University |
||
|
研究负责人所在单位: |
南京医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Nanjing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-SR-362 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京医科大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethical Committee of the First Affiliated Hospital of Nanjing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-04 00:00:00 |
||
|
伦理委员会联系人: |
柴怡 |
||
|
Contact Name of the ethic committee: |
Chai Yi |
||
|
伦理委员会联系地址: |
南京市广州路300号南京医科大学第一附属医院(江苏省人民医院)药学楼3楼 |
||
|
Contact Address of the ethic committee: |
3rd Floor of Pharmacy Building, The First Affliated Hoapital of Nanjing Medical University, 300 Guangzhou Road, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 6830 6360 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
南京市广州路300号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
300 Guangzhou Road, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
Target disease: |
Mild cognitive impairment |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探究对于轻度认知障碍患者(抑郁状态)人群,应用基于情感的中枢刺激结合外周干预方式是否比常规认知干预,更能促进患者认知功能的改善。 |
||||||||||||||||||||||
|
Objectives of Study: |
Exploring whether using emotion based central stimulation combined with peripheral intervention can better promote cognitive function improvement in patients with mild cognitive impairment (depressive state) compared to conventional cognitive intervention. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、2006 年 MCI 国际工作组及 2008 年我国轻度认知损害临床研究指导原则(① 来自患者和 / 或家庭成员的认知主诉;② 患者和 / 或知情者报告在过去 1 年内相对于先前的认知功能下降;③ 认知障碍由临床评估证实,表现为记忆和 / 或其他认知领域出现损害;④ 日常生活活动保存,复杂的工具性机能未受损或仅有非常轻微的损害;⑤ 无痴呆。);2、年龄 50~85 岁;3、 8≤HAMD-17≤24分;4、临床痴呆分级量表( CDR )0.5 分;5、无功能核磁检查禁忌证且能配合完成检查;6、能配合完成所有训练方案及包含的神经心理测试者;7、同意参加本临床试验,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. The 2006 MCI International Working Group and the 2008 Clinical Research Guidelines for Mild Cognitive Impairment in China (① Cognitive complaints from patients and/or family members; ② Patients and/or informants reporting a relative decline in cognitive function over the past year; ③ Cognitive impairment confirmed by clinical evaluation, manifested as impairment in memory and/or other cognitive domains; ④ Preservation of daily life activities, complex instrumental functions not impaired or only very mild impairment; ⑤ No dementia); 2. Age range from 50 to 85 years old; 3. 8 ≤ HAMD-17 ≤ 24 points; 4. Clinical Dementia Rating Scale (CDR) 0.5 points; 5. No contraindications for functional magnetic resonance imaging and able to cooperate in completing the examination; 6. Capable of cooperating in completing all training programs and including neuropsychological tests; 7. Agree to participate in this clinical trial and sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1、体内存在心脏支架、起搏器、假牙及人工耳蜗等顺铁磁性金属植入物; 2、存在难治性癫痫、正常压力性脑积水、脑部肿瘤等神经系统疾病; 3、DSM-5 或 ICD-10诊断的精神发育迟滞、双向情感障碍、精神分裂症等,或目前正在服用抗精神病相关药物者; 4、严重心肺疾病及肝肾功能障碍者; 5、严重的视听觉功能障碍; 6、研究者认为不宜参加本临床试验的受试者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. There are paramagnetic metal implants such as heart stents, pacemakers, dentures, and cochlear implants in the body; 2. Existence of intractable epilepsy, normal stress induced hydrocephalus, brain tumors and other neurological diseases; 3. Individuals diagnosed with mental retardation, bipolar disorder, schizophrenia, etc. by DSM-5 or ICD-10, or currently taking antipsychotic drugs; 4. Severe heart and lung diseases and liver and kidney dysfunction; 5. Severe visual and auditory dysfunction; 6. The researchers believe that participants who are not suitable to participate in this clinical trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-01 00:00:00至 To 2025-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-08-01 00:00:00 至 To 2025-02-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由治疗师将患者完全随机按照1:1比例分为2组,应用R软件生成随机数字,形成随机数字序列,将数字大小排列,将1-33分配到认知干预组,将34-66分配到认知及情感干预联合组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The therapist completely randomized the patients into two groups in a 1:1 ratio, generated random numbers using R software to form a random number sequence, arranged the numbers in order of size, assigned 1-33 to the cognitive intervention group, and assigned 34-66 to the combined cognitive and emotional intervention group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025年12月31日开始公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Sharing IPD since December 31th,2025 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集使用CRF表,数据管理采用数据录入和管理系统(自己设计表格手动录入) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection uses CRF tables, and data management uses data entry and management systems (manually enter self-designed tables) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |